Thank you to our Foundational and Sustaining members
As the pandemic winds down, clinical trials, product development and product commercialization are once again ramping up. That means more innovative pharmaceuticals, medical devices, software programs, biologics and other life-altering therapies will soon be more readily available to those who need them. That positive news also carries the potential for a variety of significant risks. […]
Prior to launching Talencio in January 2008, I had a successful career as an accounting executive for several medical device companies. I played a key role in successful liquidity events and raised $200M in financing. Building on my experience within the health technology sector, Talencio is the expression of my real passion: helping others succeed. […]
MINNEAPOLIS (June 9, 2020) – Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the enrollment of their first patient in the company’s VAPOR 1 clinical study. VAPOR 1 is an early feasibility study evaluating the safety […]
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridiodes difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent […]
Via Francis Medical “Like most companies, Francis Medical is facing several unique challenges brought on by the coronavirus pandemic. However, unlike many companies facing the prospect of lost revenues, the real enemy of a pre-revenue startup company, like Francis Medical, is lost time. ‘Every day of delay to our timeline could mean one day later […]
Prism Clinical Research (a Nucleus Network company) is playing a key role in supporting the University of Minnesota as it commences trialling a COVID-19 prevention treatment targeting frontline healthcare workers and first responders. David Boulware, MD, MPH, a professor in the University of Minnesota Medical School’s Department of Medicine in the Division of Infectious Diseases […]
Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis […]
Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]
The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics The landmark trial endpoint approach aligns with commentary at a recent FDA Public Workshop on biomarkers for heart failure clinical trials To date, hundreds of thousands of hours of continuous multivariate sensor data […]
MINNEAPOLIS, MN— August 6, 2019 — SilkTech Biopharmaceuticals, a biotechnology company focused on the development of novel therapies to treat Dry Eye Disease (DED), today announced the completion of their Phase 2B clinical trial enrollment to assess the safety and efficacy of the company’s SDP-4 ophthalmic eye-drop formulation to treat the signs and symptoms of DED. […]